Medicare & GLP-1 Coverage:
What It Means
For You

For years, one of the biggest barriers to GLP-1 medications wasn’t the science. It wasn’t the side effects. It was the price tag. A monthly supply of semaglutide could run $900 to $1,300 out of pocket — a number that put it out of reach for most people on fixed incomes or without generous insurance. As of July 1, 2026, that changed for millions of Medicare beneficiaries.

The Medicare GLP-1 Bridge launched on July 1, 2026. It is a CMS demonstration project that provides eligible Medicare Part D beneficiaries with access to certain GLP-1 medications at a fixed $50 monthly copay — no deductible, no prior year spending required. The program runs through December 31, 2027.

But I want to be honest with you about what this means — and what it doesn’t.

What the Medicare GLP-1 Bridge Covers

Three medications are covered under the Bridge program as of July 2026:

• Foundayo® — oral semaglutide tablet (a newer formulation for people who prefer not to inject)
• Wegovy® — semaglutide injection or tablet
• Zepbound® KwikPen only — tirzepatide injection. Note: single-dose vials and pens are not covered under this program.

The program operates outside the standard Medicare Part D benefit payment flow. This means the Part D deductible does not apply, and the $50 copay does not count toward your out-of-pocket maximum (TrOOP). Low-income subsidy (LIS/Extra Help) does not apply to Bridge program copays either.

Who Qualifies

To be eligible, you must be 18 or older, have Medicare Part D coverage, and meet one of the following BMI-based criteria:

You are not eligible if you already receive GLP-1 coverage through your existing Medicare Part D plan, or if you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease — though your Part D plan may separately cover GLP-1s for those conditions.

There is one requirement that often gets overlooked: your prescribing provider must certify that you are using the GLP-1 medication as part of a lifestyle program focused on diet and exercise. This is not a formality. It is a clinical requirement, and it reflects exactly what the research shows — medication works best when it is part of a broader behavioral strategy.

Will This Solve the Obesity Epidemic?

It will help. But it won’t solve it by itself.

Making GLP-1 medications more affordable means many people who couldn’t previously access treatment now can. That is a major step forward and has the potential to improve the health of millions of Americans. I don’t want to minimize that. Reducing the financial barrier to a clinically effective treatment is genuinely good news.

But medication isn’t the entire answer. And I say that as someone who used a GLP-1 as part of my own journey.

That’s not a criticism of the medication. It’s a description of what it actually does. Semaglutide and similar drugs work by reducing hunger signals and slowing gastric emptying. They make it easier to eat less. They don’t make it automatic. And they certainly don’t teach you what to do when you stop taking them.

The Part Nobody Talks About

The research on GLP-1 discontinuation is sobering. Studies consistently show that when people stop taking these medications — whether by choice, due to side effects, or because of cost — a significant portion of the lost weight returns within months. In some studies, participants regained two-thirds of their lost weight within a year of stopping.

This isn’t a failure of the medication. It’s a predictable outcome when the underlying behaviors haven’t changed. The drug suppressed appetite. The habits were never built. When the drug goes away, the old patterns return — because they were never replaced with anything durable.

The Core Principle

The goal isn’t simply to lose weight. The goal is to build a way of living that allows you to keep it off — whether you’re taking a GLP-1 or not.

I lost 170 pounds over 18 months. I used a GLP-1 as one part of a system. But the system — tracking calories, understanding my numbers, building sustainable habits around food and movement — was the foundation. The medication made it easier to stay in a deficit. The system made it possible to stay there for life.

What This Means If You’re on Medicare

If you qualify for the expanded Medicare coverage, I think you should seriously consider it. Lower cost means fewer barriers, and fewer barriers means more people get a real shot at meaningful weight loss. That’s worth celebrating.

But I’d encourage you to think of the medication as the beginning of a process, not the solution itself. Use the reduced appetite as a window. Use that window to learn your calorie targets, build your tracking habits, understand what sustainable eating looks like for your body and your life.

Because the medication will eventually end. The habits you build while taking it are what determine what happens next.

The best results I’ve seen — in my own journey and in the people I coach — come from combining medication (when appropriate) with a sustainable system that can continue working whether you’re taking a GLP-1 or not. That combination is powerful. The medication alone is not.

The Bottom Line

Medicare expanding GLP-1 access is good news. More people will be able to afford a medication that genuinely helps with weight loss. That matters.

But the obesity epidemic isn’t a medication access problem at its core. It’s a behavior and knowledge problem — one that medication can assist with but cannot solve on its own. The people who will benefit most from this expansion are the ones who use it as a tool within a larger system, not as a replacement for one.

If you want to understand how to build that system — the one that works with or without a GLP-1 — that’s exactly what I teach.

← Back to Resources